Given MDM2’s p53-independent role in initiation ... used to find differentially expressed genes. The mean gene expression of each liposarcoma subtype was used to calculate the fold change ...

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma ... of the MDM2 gene. At the moment, the only ...

The results showed that 24 of 32 patients with de-differentiated liposarcoma and MDM2 amplification had stable disease and four other patients had partial responses for a disease control rate of ...

Rain licensed the drug from Daiichi based on phase 1 data showing “meaningful antitumor activity” in a subtype of liposarcoma and other solid tumors in which the MDM2 gene is amplified.

Liposarcomas are universally characterized by amplification of the mouse double minute 2 homolog (MDM2) gene, which leads ... from a study of BTX-A51 in human liposarcoma (LPS) conducted by ...

Besides liposarcoma, the therapy is in development ... an inhibitor of the MDM2 gene that drives many cancers. The target has been around for a long time but has so far eluded drugmakers ...

in various solid tumors including phase 1 study in WD/DD LPS (liposarcoma). These types of tumors have nearly universal MDM2 gene amplification and WT p53 (thus are nearly universally MDM2-dependent).

Please provide your email address to receive an email when new articles are posted on . Sandra D’Angelo, MD, discussed initial phase 1A/1B data from a clinical trial on the efficacy and safety ...

New York, USA, May 27, 2025 (GLOBE NEWSWIRE) -- Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight The liposarcoma ...

Dedifferentiated liposarcoma is a highly morbid mesenchymal tumor accounting for approximately 20% of all soft-tissue sarcomas" MDM2 degrades p53, thus, an amplification in MDM2 results in reduced ...